(VIRP) Virbac - Ratings and Ratios
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR0000031577
Vaccines, Antibiotics, Parasiticides, Dermatology, Petfood
| Risk via 10d forecast | |
|---|---|
| Volatility | 30.0% |
| Value at Risk 5%th | 41.3% |
| Reward | |
|---|---|
| Sharpe Ratio | 0.41 |
| Alpha Jensen | 0.23 |
| Character | |
|---|---|
| Hurst Exponent | 0.600 |
| Beta | 0.925 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.85% |
| Mean DD | 11.38% |
Description: VIRP Virbac November 09, 2025
Virbac SA (ticker VIRP) is a French-based, globally diversified animal health company that develops, manufactures, and markets vaccines, antibiotics, parasiticides, anti-inflammatory drugs, and a broad portfolio of ancillary products-including dermatology, dental, diagnostic, nutrition, and pet-food solutions-for companion animals, livestock, and equine markets. Founded in 1968 and headquartered in Carros, France, the firm serves veterinarians, farmers, and pet owners across Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific.
Key recent metrics: 2023 revenue reached €2.6 billion, up ~5 % YoY, driven by a 7 % rise in pet-care sales and a 3 % increase in livestock-health products; R&D intensity averaged 9 % of sales, reflecting a focus on novel biologics and antimicrobial-resistance-free solutions. Sector drivers include sustained growth in global pet ownership (projected CAGR 5 % through 2028) and rising protein demand in emerging markets, which together underpin demand for preventive vaccines and therapeutic agents.
For a deeper quantitative assessment, you may find ValueRay’s analyst notes on VIRP useful.
VIRP Stock Overview
| Market Cap in USD | 3,442m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | |
| Return 12m vs S&P 500 | -6.58% |
| Analyst Rating | - |
VIRP Dividends
| Dividend Yield | 0.41% |
| Yield on Cost 5y | 0.71% |
| Yield CAGR 5y | 20.74% |
| Payout Consistency | 82.1% |
| Payout Ratio | 9.1% |
VIRP Growth Ratios
| CAGR | 14.80% |
| CAGR/Max DD Calmar Ratio | 0.50 |
| CAGR/Mean DD Pain Ratio | 1.30 |
| Current Volume | 2.8k |
| Average Volume | 4.1k |
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income (274.0m TTM) > 0 and > 6% of Revenue (6% = 166.3m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 4.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.85% (prev 35.92%; Δ -21.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.18 (>3.0%) and CFO 327.0m > Net Income 274.0m (YES >=105%, WARN >=100%) |
| Net Debt (197.0m) to EBITDA (500.8m) ratio: 0.39 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (8.38m) change vs 12m ago -0.93% (target <= -2.0% for YES) |
| Gross Margin 66.56% (prev 33.87%; Δ 32.69pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 171.3% (prev 85.19%; Δ 86.13pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 19.01 (EBITDA TTM 500.8m / Interest Expense TTM 21.1m) >= 6 (WARN >= 3) |
Altman Z'' 4.78
| (A) 0.23 = (Total Current Assets 842.2m - Total Current Liabilities 430.5m) / Total Assets 1.82b |
| (B) 0.05 = Retained Earnings (Balance) 82.4m / Total Assets 1.82b |
| (C) 0.25 = EBIT TTM 401.5m / Avg Total Assets 1.62b |
| (D) 1.41 = Book Value of Equity 1.06b / Total Liabilities 750.3m |
| Total Rating: 4.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.79
| 1. Piotroski 9.50pt = 4.50 |
| 2. FCF Yield 5.94% = 2.97 |
| 3. FCF Margin 6.79% = 1.70 |
| 4. Debt/Equity 0.31 = 2.45 |
| 5. Debt/Ebitda 0.39 = 2.38 |
| 6. ROIC - WACC (= 12.66)% = 12.50 |
| 7. RoE 27.38% = 2.28 |
| 8. Rev. Trend 92.29% = 6.92 |
| 9. EPS Trend 1.61% = 0.08 |
What is the price of VIRP shares?
As of November 14, 2025, the stock is trading at EUR 357.00 with a total of 2,821 shares traded.
Over the past week, the price has changed by +5.62%, over one month by +13.51%, over three months by +8.35% and over the past year by +6.41%.
Over the past week, the price has changed by +5.62%, over one month by +13.51%, over three months by +8.35% and over the past year by +6.41%.
Is Virbac a good stock to buy?
Yes, based on ValueRay´s Fundamental Analyses, Virbac (PA:VIRP) is currently (November 2025)
a good stock to buy. It has a ValueRay Fundamental Rating of 85.79 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VIRP is around 330.89 EUR . This means that VIRP is currently overvalued and has a potential downside of -7.31%.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VIRP is around 330.89 EUR . This means that VIRP is currently overvalued and has a potential downside of -7.31%.
Is VIRP a buy, sell or hold?
Virbac has no consensus analysts rating.
What are the forecasts/targets for the VIRP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 403.2 | 12.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 369.2 | 3.4% |
VIRP Fundamental Data Overview January 01, 1970
Market Cap USD = 3.44b (2.97b EUR * 1.159 EUR.USD)
Market Cap EUR = 2.97b (2.97b EUR * 1.0 EUR.EUR)
P/E Trailing = 21.7391
P/S = 2.0729
P/B = 2.5407
Beta = 0.925
Revenue TTM = 2.77b EUR
EBIT TTM = 401.5m EUR
EBITDA TTM = 500.8m EUR
Long Term Debt = 203.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 97.5m EUR (from shortTermDebt, last quarter)
Debt = 325.6m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 197.0m EUR (from netDebt column, last quarter)
Enterprise Value = 3.17b EUR (2.97b + Debt 325.6m - CCE 128.7m)
Interest Coverage Ratio = 19.01 (Ebit TTM 401.5m / Interest Expense TTM 21.1m)
FCF Yield = 5.94% (FCF TTM 188.2m / Enterprise Value 3.17b)
FCF Margin = 6.79% (FCF TTM 188.2m / Revenue TTM 2.77b)
Net Margin = 9.88% (Net Income TTM 274.0m / Revenue TTM 2.77b)
Gross Margin = 66.56% ((Revenue TTM 2.77b - Cost of Revenue TTM 927.1m) / Revenue TTM)
Gross Margin QoQ = 67.38% (prev 65.49%)
Tobins Q-Ratio = 1.74 (Enterprise Value 3.17b / Total Assets 1.82b)
Interest Expense / Debt = 1.54% (Interest Expense 5.00m / Debt 325.6m)
Taxrate = 33.68% (41.8m / 124.0m)
NOPAT = 266.3m (EBIT 401.5m * (1 - 33.68%))
Current Ratio = 1.96 (Total Current Assets 842.2m / Total Current Liabilities 430.5m)
Debt / Equity = 0.31 (Debt 325.6m / totalStockholderEquity, last quarter 1.07b)
Debt / EBITDA = 0.39 (Net Debt 197.0m / EBITDA 500.8m)
Debt / FCF = 1.05 (Net Debt 197.0m / FCF TTM 188.2m)
Total Stockholder Equity = 1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.09% (Net Income 274.0m / Total Assets 1.82b)
RoE = 27.38% (Net Income TTM 274.0m / Total Stockholder Equity 1.00b)
RoCE = 33.33% (EBIT 401.5m / Capital Employed (Equity 1.00b + L.T.Debt 203.9m))
RoIC = 21.25% (NOPAT 266.3m / Invested Capital 1.25b)
WACC = 8.59% (E(2.97b)/V(3.30b) * Re(9.42%) + D(325.6m)/V(3.30b) * Rd(1.54%) * (1-Tc(0.34)))
Discount Rate = 9.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.22%
[DCF Debug] Terminal Value 69.07% ; FCFE base≈144.5m ; Y1≈115.3m ; Y5≈77.9m
Fair Price DCF = 137.7 (DCF Value 1.15b / Shares Outstanding 8.38m; 5y FCF grow -24.16% → 3.0% )
EPS Correlation: 1.61 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 92.29 | Revenue CAGR: 20.26% | SUE: 1.06 | # QB: 1
Market Cap EUR = 2.97b (2.97b EUR * 1.0 EUR.EUR)
P/E Trailing = 21.7391
P/S = 2.0729
P/B = 2.5407
Beta = 0.925
Revenue TTM = 2.77b EUR
EBIT TTM = 401.5m EUR
EBITDA TTM = 500.8m EUR
Long Term Debt = 203.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 97.5m EUR (from shortTermDebt, last quarter)
Debt = 325.6m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 197.0m EUR (from netDebt column, last quarter)
Enterprise Value = 3.17b EUR (2.97b + Debt 325.6m - CCE 128.7m)
Interest Coverage Ratio = 19.01 (Ebit TTM 401.5m / Interest Expense TTM 21.1m)
FCF Yield = 5.94% (FCF TTM 188.2m / Enterprise Value 3.17b)
FCF Margin = 6.79% (FCF TTM 188.2m / Revenue TTM 2.77b)
Net Margin = 9.88% (Net Income TTM 274.0m / Revenue TTM 2.77b)
Gross Margin = 66.56% ((Revenue TTM 2.77b - Cost of Revenue TTM 927.1m) / Revenue TTM)
Gross Margin QoQ = 67.38% (prev 65.49%)
Tobins Q-Ratio = 1.74 (Enterprise Value 3.17b / Total Assets 1.82b)
Interest Expense / Debt = 1.54% (Interest Expense 5.00m / Debt 325.6m)
Taxrate = 33.68% (41.8m / 124.0m)
NOPAT = 266.3m (EBIT 401.5m * (1 - 33.68%))
Current Ratio = 1.96 (Total Current Assets 842.2m / Total Current Liabilities 430.5m)
Debt / Equity = 0.31 (Debt 325.6m / totalStockholderEquity, last quarter 1.07b)
Debt / EBITDA = 0.39 (Net Debt 197.0m / EBITDA 500.8m)
Debt / FCF = 1.05 (Net Debt 197.0m / FCF TTM 188.2m)
Total Stockholder Equity = 1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.09% (Net Income 274.0m / Total Assets 1.82b)
RoE = 27.38% (Net Income TTM 274.0m / Total Stockholder Equity 1.00b)
RoCE = 33.33% (EBIT 401.5m / Capital Employed (Equity 1.00b + L.T.Debt 203.9m))
RoIC = 21.25% (NOPAT 266.3m / Invested Capital 1.25b)
WACC = 8.59% (E(2.97b)/V(3.30b) * Re(9.42%) + D(325.6m)/V(3.30b) * Rd(1.54%) * (1-Tc(0.34)))
Discount Rate = 9.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.22%
[DCF Debug] Terminal Value 69.07% ; FCFE base≈144.5m ; Y1≈115.3m ; Y5≈77.9m
Fair Price DCF = 137.7 (DCF Value 1.15b / Shares Outstanding 8.38m; 5y FCF grow -24.16% → 3.0% )
EPS Correlation: 1.61 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 92.29 | Revenue CAGR: 20.26% | SUE: 1.06 | # QB: 1